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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: Typhoid fever is a major cause of disease burden in developing coun-
tries. The use of fluoroquinolones, once considered the drugs of choice, should be re-
evaluated due to the emergence of quinolone-resistant Salmonella enterica serovar Typhi.
In Taiwan, typhoid fever is rare but constitutes an important public health concern.
Methods: In August 2011, two ciprofloxacin-resistant S. Typhi isolates were identified from one
patient who had recently travelled to India. The two isolates together with four other
ciprofloxacin-susceptible S. Typhi isolates were subjected for molecular investigation. Poly-
merase chain reaction (PCR) and sequencing were used to analyze the resistance mechanisms.
Pulsed-field gel electrophoresis (PFGE) was performed to delineate the genetic relatedness
among the isolates.
Results: In 2011, a total of 49 typhoid fever cases were reported to the Center for Disease Con-
trol in Taiwan, with a significant increase in indigenous cases in northern Taiwan from August
to November. In the two S. Typhi isolates with complete resistance to ciprofloxacin [minimum
inhibitory concentration (MIC) >32 mg/mL], multiple point mutations in the quinolone
resistance-determining regions (QRDRs) of gyrA and parC genes were identified. A unique PFGE
pattern was found in the resistant isolates and was different from the other representative sus-
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470 C.-J. Lee et al.Conclusions: The first ciprofloxacin-resistant S. Typhi infection in Taiwan is reported. The
emergence and spread of antimicrobial-resistant S. Typhi infection as a result of international
travel may become a threat to public health in Taiwan. Clinicians should be well alert when
treating patients who may have acquired resistant infections associated with international tra-
vel among endemic regions.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Typhoid fever is a systemic infectious disease caused by
Salmonella enterica serovar Typhi. It is a major cause of
disease burden in developing countries. In 2000, typhoid
fever resulted in approximately 21.7 million illnesses and
216.5 thousand deaths according to a report by the World
Health Organization.1
Typhoid fever may lead to prolonged fever, severe diar-
rhea, gastrointestinal bleeding, bowel perforation, and
death. A timely, appropriate antimicrobial treatment is cru-
cial to improve the disease outcome. Effective antimicrobial
regimens for typhoid fever may include ampicillin, chlor-
amphenicol, and trimethoprim/sulfamethoxazole in the past.
However, in the last 20 years, the worldwide emergence of
multidrug-resistant (MDR) S. Typhi has become a cause of
concern.2,3 Third-generation cephalosporins and fluo-
roquinolones are hence considered the drugs of choice if
typhoid fevercausedbyMDRstrains is suspected.4e7However,
nalidixic acid-resistant S. Typhi (NARST) with a reduced sus-
ceptibility tociprofloxacin hasbecomeanendemicproblem in
south and southeast Asia for thepast 10years.2,8e10NARSThas
also been reported in the United Kingdom, United States, and
other developed countries.11e13 The drug resistance of S.
Typhi makes treatment more difficult and costly.
Typhoid fever, although rare, is a notifiable disease in
Taiwan. Once a diagnosis or suspicion of typhoid fever has
been established, clinicians must report it to the public
health authorities within 24 h. According to the Center for
Disease Control in Taiwan (CDC, Taiwan), the annual num-
ber of typhoid fever cases, including indigenous and im-
ported cases, has remained low at less than 50 in the past 5
years (http://www.cdc.gov.tw/). Antimicrobial resistance
is also uncommon, and ciprofloxacin resistance has never
been reported previously in S. Typhi.14
In this study, we present the first case of ciprofloxacin-
resistant S. Typhi in Taiwan. Sequencing of the quinolone
resistance-determining regions (QRDRs) and comparison of
pulsed-field gel electrophoresis (PFGE) patterns between
this resistant strain and other nonresistant isolates of
S. Typhi were performed.Methods
Setting
Chang Gung Memorial Hospital (CGMH) is a 3500-bed
university-affiliated hospital located in northern Taiwan.
The Clinical Microbiology Laboratory in CGMH is anaccredited laboratory of the College of American Patholo-
gists and is responsible for the microbial culture examina-
tion of all clinical specimens from this hospital.Bacterial identification and antimicrobial
susceptibility testing
All specimens submitted for microbial isolation and identi-
fication have been handled by standard methods. Serotyp-
ing of Salmonella isolates was further assessed by the O and
H antisera (Difco Laboratories, Detroit, MI, USA) using
standard methods and the results were interpreted ac-
cording to the KauffmaneWhite scheme.15 Antimicrobial
susceptibility was investigated by the standard disc dif-
fusion method. The antimicrobial agents examined inclu-
ded ampicillin, cefixime, ceftriaxone, chloramphenicol,
ciprofloxacin, ertapenem, flomoxef, imipenem, and tri-
methoprim/sulfamethoxazole. Susceptibility and resist-
ance were defined according to the guidelines described by
the Clinical and Laboratory Standards Institute (CLSI).16 The
minimum inhibitory concentrations (MICs) of ciprofloxacin
was determined by the E-test (AB BIODISK, Solna, Sweden).
Ciprofloxacin resistance was defined as MIC >4 mg/mL.16Characterization of ciprofloxacin-resistant isolates
Two ciprofloxacin-resistant S. Typhi isolates were identified
from one patient in August 2011. The medical records of the
patient were reviewed. The number of typhoid fever cases
identified at CGMH and those published in the notifiable
infectious diseases statistics system of the CDC, Taiwan
(http://nidss.cdc.gov.tw/) in 2011 were analyzed for
comparison.
To investigate the associated resistance mechanisms,
the two resistant isolates together with other four
ciprofloxacin-susceptible S. Typhi isolates identified from
the same laboratory during July and September 2011 were
subjected for molecular examination. Genetic relatedness
of the isolates was investigated by PFGE as previously
described.17 The results were interpreted according to the
recommendations of Tenover et al.18
Polymerase chain reaction (PCR) and sequencing were
used to analyze the QRDRs of genes encoding the DNA gyrase
(gyrA and gyrB) and topoisomerase IV (parC and parE ) sub-
units.19 The results were compared with those of Salmonella
enterica serovar Typhimurium LT2 published in the public
domains. Salmonella enterica serovar Choleraesuis SCB-67,
also a ciprofloxacin-resistant isolate previously published
from this laboratory, was used as a control.20
Figure 1. Typhoid fever (including indigenous and imported
cases) in Taiwan, 2011 (http://nidss.cdc.gov.tw/). Cases
reported from Chang Gung Memorial Hospital (CGMH) are
indicated individually. One CGMH case in August was an im-
ported case with ciprofloxacin resistance.
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A total of 49 typhoid fever cases, including 42 indigenous
cases, were reported to CDC, Taiwan in 2011 (Fig. 1).
Among them, 36 of the indigenous cases were from north-
ern Taiwan. The number of typhoid fever cases that
exceeded the epidemic threshold occurred from April to
May and from August to November. A typhoid fever out-
break that occurred during April had been identified and
reported by CDC (data not shown). From August to
November, the indigenous cases increased significantly,
especially in the northern areas of Taiwan; however, no
outbreaks were confirmed.
At CGMH, 10 isolates from nine typhoid fever cases were
identified in 2011 (Fig. 1). All of them were found between
July and October. Although the majority of the S. Typhi
isolates were susceptible to all antimicrobial agents tested,
two ciprofloxacin-resistant S. Typhi isolates were identified
from one of the typhoid fever cases in August (Fig. 1). The
isolates were resistant to ciprofloxacin with MICs >32 mg/Table 1 Ciprofloxacin susceptibility and analysis of the
quinolone resistance-determining regions (QRDRs) of DNA
gyrase and topoisomerase IV subunits in six clinical isolates
of Salmonella enterica serovar Typhi
Isolate Specimen MIC (mg/mL) gyrAa parCa
Ser (83) Asp (87) Ser (80)
ST-898 Blood 0.016 Ser Asp Ser
ST-899 Blood >32 Phe Asn Ile
ST-900 Stool >32 Phe Asn Ile
ST-904 Blood 0.016 Ser Asp Ser
ST-909 Blood 0.016 Ser Asp Ser
ST-911 Blood 0.016 Ser Asp Ser
a Amino acid changes compared with the quinolone
resistance-determining regions of gyrA (codons 83 and 87) and
parC (codon 80) in Salmonella enterica serovar Typhimurium
LT2. No mutation was found in gyrB and parE.
Asn Z asparagine; Asp Z aspartic acid; Ile Z isoleucine;
PheZ phenylalanine; SerZ serine; MICZ minimum inhibitory
concentration.mL, but remained susceptible to all other antimicrobial
agents tested (Table 1). The case was a 22-year-old female
patient who had been in India for 2 weeks. Three days after
returning to Taiwan, she developed fever and gastro-
intestinal symptoms. Because of persistent fever and diar-
rhea, which showed no response to symptomatic
treatment, she visited our emergency department. After
blood sampling and physical examination, which revealed
nonspecific findings, the patient was discharged with oral
form of ciprofloxacin under the suspicion of enteric fever.
Her blood culture later revealed the presence of S. Typhi
(ST-899). The patient was then admitted to the hospital and
treated with ceftriaxone via intravenous route. During
hospitalization, the same resistant isolate was found from
her stool (ST-900). She recovered without complications
after completing the antimicrobial treatment for 9 days.
The two ciprofloxacin-resistant isolates, ST-899 and ST-
900, were subsequently proved to be the same strain by
PFGE analysis (Fig. 2). Another two different PFGE patterns
were found in the remaining four ciprofloxacin-susceptible
S. Typhi isolates, with three of them (ST-904, ST-909, and
ST-911) sharing one major PFGE pattern (Fig. 2). Analysis of
the QRDRs of DNA gyrase and topoisomerase IV subunits
revealed two point mutations in the gyrA gene and another
mutation in parC from the two ciprofloxacin-resistant iso-
lates, ST-899 and ST-900, identical to those previously
found in S. Choleraesuis SC-B67 (Table 1). In gyrA, the first
mutation consisted of a substitution of phenylalanine (Phe)
for serine (Ser) at codon 83, and the second a substitution
of asparagine (Asn) for aspartic acid (Asp) at codon 87. In
parC, the point mutation was found at codon 80 with
a substitution of isoleucine (Ile) for serine (Ser) (Table 1).
No mutations were found in gyrB and parE genes. As
expected, no mutations were detected in the four
ciprofloxacin-susceptible isolates.Figure 2. Pulsed-field gel electrophoresis patterns of
ciprofloxacin-resistant Salmonella enterica serovar Typhi iso-
lates (ST-899 and ST-900) and other representative non-
resistant isolates from Chang Gung Memorial Hospital.
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In Taiwan, typhoid fever remains an uncommon disease, but
sporadic cases do occur. Individuals who had a recent travel
to an endemic area aswell as expatriate employees were the
main sources of such patients.14 Unlike nontyphoid Salmo-
nella, antibiotic resistance has not been an issue for S. Typhi
in Taiwan.21 Fluoroquinolones and third-generation cepha-
losporins are the most adequate choices in the treatment of
typhoid fever. In this study, we reported the first case of
ciprofloxacin-resistant S. Typhi infection in Taiwan. The
resistance was due to multiple point mutations in the QRDRs
of gyrA and parC, similar to those reported previously.20,22
The patient had a recent travel history and ciprofloxacin
was prescribed empirically. Due to the ciprofloxacin resist-
ance expressed by the disease-causing strain, the patient
had to re-admit to the hospital for further treatment.
In the past 10 years, the emergence of ciprofloxacin-
resistant S. Typhi has been increasingly reported in devel-
oping countries, particularly in south and southeast Asia,
and in developed countries, such as the United States and
United Kingdom.11,23e25 Almost all of the reported cases
from these developed countries were associated with
a prior travel history to an endemic area. Morita et al.
reported the emergence of high-level fluoroquinolone-
resistant S. Typhi during 2001 and 2006 in Japan and
indicated that south Asia was deemed to be a particularly
high-risk travel destination.26 Our finding in the present
study also coincided with these reports. India is in the
typhoid fever endemic area and quinolone resistance is high
among their local S. Typhi isolates.3,10,22,27 Disease onset in
our patient occurred 3 days after her return from India and
so an infection caused by an antimicrobial-resistant strain
should be well alerted. For patients who are associated
with a recent travel history to areas with a high prevalence
of drug-resistant S. Typhi, ciprofloxacin as the first-line
empirical therapy for enteric fever should be reconsidered.
The PFGE pattern of our ciprofloxacin-resistant isolates
was identical to that reported in a previous study con-
ducted in the United States.12 Medalla et al. reported nine
ciprofloxacin-resistant S. Typhi isolates from 1999 to
2008.12 In that study, nearly all of the cases had travelled to
India before the infection. Three of their cases had iden-
tical PFGE patterns and the same antibiogram; two of them
had traveled to India. The results suggest that the
ciprofloxacin-resistant S. Typhi isolates studied herein were
imported from India; it appears to have been prevalent in
India for several years, thereby identified by both Medalla
et al. and our group.
Vaccination is suggested by the World Health Organiza-
tion for all travelers, regardless of the duration of their stay
in typhoid-endemic countries. Steinberg et al. reported
that among the travel-associated cases of typhoid fever
diagnosed in the United States during 1994e1999, 37% of
the cases occurred in travelers who stayed at their travel
destination for less than 4 weeks, and 16% occurred in those
who stayed for less than 2 weeks.28 In the present study,
the patient had traveled to India for only 2 weeks, but
acquired the infection. Prevention of S. Typhi infection
among travelers is crucial because international travel has
become an important route for the transmission of thedisease. Government and public health authorities should
be more aggressive in promoting immunization for in-
dividuals, especially for those who plan to travel to
endemic regions.
During the investigation, we incidentally found that one
particular PFGE pattern was shared by three of the four
ciprofloxacin-susceptible S. Typhi isolates that were
recovered from clinical specimens between August and
September. An apparent increase of typhoid fever cases,
predominantly in northern Taiwan, was also noted from the
notifiable infectious diseases statistics system of the CDC,
Taiwan during the latter half of the year 2011. Whether or
not the increase was due to the spread of an epidemic
strain, which was coincidently demonstrated among our
ciprofloxacin-susceptible S. Typhi control isolates, will
need further laboratory evidence.
In conclusion, the first case of ciprofloxacin-resistant
S. Typhi infection in Taiwan is reported herein. Although
this may represent the start of the resistant typhoid fever
history in Taiwan, fortunately, to the best of our knowl-
edge, no other similar cases have been further reported to
date. Personal hygiene education, adequate isolation pre-
caution policy, and appropriate antimicrobial therapy are
all effective strategies in preventing the transmission of the
disease. The populations of expatriate employees and
overseas travelers from endemic countries have increased
in the past decades. Government and public health au-
thorities should be well prepared for the prevention of
communicable resistant infections, such as the one repor-
ted herein. Clinicians should also be more alert in the
adjustment of therapeutic regimens for patients who may
have acquired resistant infection from other highly
endemic countries.
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